Lupin’s Goa facility inspection concluded by US FDA without any observations


Pharma major Lupin Limited (Lupin) announced today the successful completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Goa manufacturing facility without any observations. The inspection which started on Monday, July 17th concluded today afternoon. 


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top